As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S.

It has two commercial products, Auvelity and Sunosi, and several products in development, including AXS-05 and AXS-07. On March 6, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Axsome Therapeutics (NASDAQ: AXSM) recently received a number of ratings updates from brokerages and research firms: 3/6/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC ...

HC Wainwright reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $200.00 price ...

In addition to its pipeline candidates, Axsome also has US rights to Jazz Pharma's dual-acting dopamine and norepinephrine reuptake inhibitor Sunosi (solriamfetol), used to improve wakefulness in ...

A federal judge granted a joint request to drop Axsome Therapeutics Inc.'s patent claims against Hikma Pharmaceuticals Plc over proposed copies of Sunosi, leaving three generic-drug makers in the ...

Jazz has added two more narcolepsy medicines to its portfolio – Sunosi (solriamfetol) and Xyrem follow-up Xywav – and last year also launched its first cancer drug, PharmaMar-partnered ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors. Uncover insightful assessments of a stock's market performance and potential with ...

After hours: March 11 at 7:40:59 PM EDT Loading Chart for AXSM ...

After hours: March 10 at 6:31:15 p.m. EDT Loading Chart for AXSM ...